-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of CDE showed that Sichuan Kelun Pharmaceutical Research Institute|Sichuan Kelun Pharmaceutical was accepted for imitation of tofacitib citrate sustained-release tablets of 3 types of applications
Data show that tofacitib is the world's first small molecule targeted JAK kinase inhibitor developed by Pfizer for the treatment of rheumatoid arthritis.
Global sales of tofacitib citrate in recent years (unit: billion U.
Source: Mynet.
According to data from Menet.
Source: One-click search on Mi Nei.
Only tofacitib citrate tablets are on the market for tofacitib, and more than 10 manufacturers include Pfizer, Zhengda Tianqing Pharmaceutical Group, Qilu Pharmaceuticals, Hunan Kelun Pharmaceuticals, etc.
At present, 4 companies of tofacitib citrate sustained-release tablets have submitted listing applications for approval.
Source: CDE official website, Minet database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories